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Introduction
Conclusion
Irritable bowel syndrome (IBS) has been defined as a poorly understood, chronic 
gastrointestinal (GI) disorder without clear physical or biochemical dysfunction, 
relating symptoms to psychological causes. Recent evidence proposes new 
understanding of the interaction between the gut and brain, with a focus on the gut 
microbiome and its role in the pathophysiology of the disorder (Ford et al., 2017). 
IBS is a common condition presenting with persistent abdominal pain, altered bowel 
habits and often bloating. Diagnosis is based upon the Rome IV criteria and use of the 
Bristol stool form scale to categorize the appropriate IBS subtype: constipation, 
diarrhea, or mixed symptoms of both (Ford et al., 2017). 
My husband has struggled with the disorder since he was a child. I have seen first-
hand how IBS can impact quality of life and the frustration with finding adequate 
treatment. Commonly encountered in the primary care setting, the advanced practice 
nurse will have an opportunity to provide care to these patients. Understanding the 
current pathophysiology and diagnostic criteria can contribute to improved outcomes. 
 Epidemiologists estimate IBS affects nearly 11% of individuals throughout the 
world.  In the United States, it is as high as 20% (Canavan et al., 2014). 
 30% of those with IBS consult healthcare services (Canavan et al., 2014).
 IBS is more common in women, sex hormones may play a role (Kim & Kim, 2018).
 A recent nationwide prospective cohort study of >45,000 individuals in Sweden 
suggests that IBS is not associated with increased mortality (Staller et al., 2020). 
 The impact of IBS on quality of life is significant and healthcare providers often 
underestimate the burden on patients (Lacy, 2019). 
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Rome IV diagnostic criteria 
IBS is a complex disorder and is 
unlikely to be narrowed to down to 
one cause as pathogenic factors that 
produce symptoms vary among 
individuals (Chong et al., 2019). This 
functional disorder has long been 
considered a dysregulation between 
the brain and gut.  Recent research 
provides new understanding of this 
relationship, with half of all cases 
originating in the gut and 
psychological symptoms following 
(Ford et al., 2017). 
Pathophysiology
 Patients with IBS report more daily and lifetime stressful events as compared to healthy 
individuals. The effects of stress on gut function is widespread, however those with IBS 
tend to have greater responsiveness to stress (Hellström, 2019). 
 Emotional and physical stress can delay gastric emptying and intestinal transit, 
disrupting the mucosal barrier causing the transmigration of bacteria leading to GI pain 
and diarrhea (Drossman, 2016). 
 Psychological stress induces the secretion of pro-inflammatory cytokines that activate 
the hypothalamic-pituitary-adrenal (HPA) axis triggering the release of stress hormones 
that affect gut homeostasis (Chong et al., 2019). 
 Inflammatory cytokines are commonly found in patients with IBS and are highly 
associated with anxiety and depression, suggesting the gut may have a role in regulating 
brain function (Chong et al., 2019). 
 Two-way communication between the gut and brain occurs via the cingulate cortex and 
peripheral GI tract.  The perception of pain is influenced by this emotional mechanism, 
allowing mental state to affect IBS symptoms (Lee et al., 2017).  The cingulate cortex in 
IBS patients is dysfunctional, in the presence of psychosocial distress, pain threshold is 
decreased (Drossman, 2016). 
 Higher levels of anxiety and depression are experienced in patients with IBS regardless 
of subtype (Lee et al., 2017). 
 Patterns of brain activation associated with anxiety may be associated with changes in 
the microbiome of patients with IBS-D (Pimentel & Lembo, 2020). 
 While serotonin is usually associated with the brain, it is found mostly in the digestive 
system and has an important role in GI motility. High levels of serotonin are associated 
IBS-D and low levels with IBS-C (Chong et al., 2019). 
Clinical Manifestations
Abdominal pain- cramping sensation with variable intensity and location. Pain is 
often relieved with defecation. Stress and meals often affect pain intensity with 
bloating and gas commonly experienced (Wald, 2019).
Altered bowel habits- includes diarrhea, constipation or a combination of both, 
which can also alternate with normal bowel habits. The Bristol stool form scale is 
used to identify stool consistency (Wald, 2019). 
IBS subtypes
Based upon predominant bowel habit on days with abnormal bowel movements.
 IBS-D (diarrhea)- frequent small volume loose stools. Often accompanied by 
abdominal cramping and sensation of incomplete evacuation. 50% of patients 
report mucus discharge. Type 6/7 Bristol stool scale. 
 IBS-C (constipation)- hard, pellet shaped stools often with sensation of 
incomplete evacuation. Type 1/2 Bristol stool scale. 
 IBS-M (mixed)- combination of diarrhea and constipation
 IBS-U (unclassified)- meets diagnostic criteria but unable to fit into one of the 
three subtypes (Wald, 2019).
The Rome IV criteria serves as the national guideline for diagnosing IBS. In the 
absence of warning signs such as unintentional weight loss, recent change in bowel 
habits, positive fecal occult blood, overt GI bleeding or iron deficiency anemia, a 
positive diagnosis can be made without subjecting the patient to unnecessary tests 
(Ford et al., 2017). 
(Heidelbaugh, 2017)
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Illustrated summary of IBS pathophysiology 
(Farmer, 2020)
Normal gut microbiota within the human 
intestine is complex, involving thousands of 
microbial species working together to maintain 
homeostasis and protect against pathogens. 
While in a constant state of change throughout 
the lifespan, environment, diet and stress can 
affect this balance. Recent studies suggest 
changes in the gut microbiome play a key role in 
IBS development (Chong et al., 2019). 
Post infection: IBS is four times higher in those 
who have had acute gastroenteritis in the last 
year. Infection severity and female sex further 
increase the risk (Pimentel & Lembo, 2020).  
Bacterial toxins following gastroenteritis lead 
to autoimmunity to vinculin, an intracellular 
protein responsible for neuronal cell motility and 
contractility in the GI tract (Pimentel & Lembo, 
2020).
Dysbiosis: An imbalance of the microbial flora 
creates dysbiosis. This alteration affects gut 
integrity and modulation of the gut 
neuromuscular junction (Chong et al., 2019). 
In glucose or lactose breath testing, small 
intestinal bacterial overgrowth is associated with 
IBS-D (Pimentel & Lembo, 2020). 
Antibiotic treatment with broad spectrum 
antibiotics can contribute to dysbiosis leading to 
the development of IBS (Hellström, 2019).
Stool transfer studies from ISB-D patients into 
animals, elicits altered intestinal motility, 
permeability and visceral hypersensitivity 
(Pimentel & Lembo, 2020).
Excess colonization of Methanobrevibacter 
smithii in the gut, produces elevated methane 
gas leading to decreased intestinal motility and 
constipation (Pimentel & Lembo, 2020). 
Inflammation/immune activation: Low grade 
intestinal mucosal inflammation can arise from a 
compromised mucosal barrier, dysbiosis, post 
infection and altered stress levels, stimulating 
abnormal immune responses found in IBS 
(Chong et al., 2019.)
Toll-like receptors are important mediators of 
intestinal immune response to gut microbes. 
Increased expression of intestinal Toll-like 
receptors is associated with IBS (Pimentel & 
Lembo, 2020). 
Increased intestinal mucosal immune markers 
such as intraepithelial lymphocytes, T cells and 
mast cells are evident in patients with IBS. Mast 
cells release substances that can sensitize 
primary afferent neurons. Large numbers of 
mast cells found close to nerves in the gut, 
correlate with abdominal pain severity 
(Hellström, 2019). 
 The breakdown of food products plays a crucial role in the development of IBS by 
affecting gut motility, the microbiome and visceral sensation (Chong et al., 2019).
 Many patients report bloating and abdominal pain after ingestion of foods containing 
fermentable oligosaccharides, disaccharides, monosaccharides and polyols 
(FODMAPs). Methane production and osmotic effects may stimulate motility and 
increase intraluminal fluid leading to bloating (Chong et al., 2019).
 Gluten may alter intestinal permeability and activate the autonomous and enteric 
nervous system leading to bloating and abdominal pain (Chong et al., 2019). 
 Research by Fritscher-Ravens et al. (2019) concludes that over 50% of patients with 
IBS may have atypical food allergies, particularly to wheat. Utilizing confocal laser 
endomicroscopy, disruption of the intestinal barrier with eosinophilic activation 
occurred with exposure to food antigens, despite delayed clinical symptoms. Long 
term follow-up found dramatically improved symptoms when food antigens were 
removed from the diet.
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Recent research has uncovered exciting new evidence and understanding of IBS. While numerous and complex, these 
perspectives are crucial to the development of effective treatments. Past management has focused on the most prevalent 
symptoms, rather than on underlying pathophysiology and as a result the long-term course of the disorder is largely 
unchanged (Holtmann et al., 2016). 
 No widely accepted treatment currently exists. Medications are only partially effective and with side effects. A multi-
disciplinary approach can provide the best outcomes in this complex disorder (Nelkowska, 2020).
 GI symptoms may be the result of poor coping strategies. Short term psychological therapy is effective in reducing 
abdominal symptoms with long term improvement (Nelkowska, 2020).  
 A low FODMAP diet can decrease abdominal pain, bloating and diarrhea by eliminating foods that produce bacterial 
fermentation in the gut, however long-term use and follow-up is lacking (Pimentel & Lembo, 2020). 
 Many gastroenterologists believe diet to be an important part of IBS treatment, however only a small percentage 
refer patients to dieticians (Nelkowska, 2020). 
 Rifaximin, a non-systemic antibiotic, has been recently approved by the Food and Drug Administration to treat    
IBS-D. Reducing small intestinal bacteria is the likely mechanism of action (Pimentel & Lembo, 2020). 
 Probiotics have a role in reducing gut inflammation and improving barrier function. Effective strains are trial and 
error. Future therapy will likely be based upon individual microbiota profiling (Chong et al., 2019). 
 Fecal transplantation is a current area of interest in improving the microbiome in IBS.  It has not yet proven 
successful given the challenge of finding the correct balance to normalize gut function (Hellström, 2019). 
Nursing Implications
A pilot study conducted by Shannon Purdy (2017), utilized a cross-
sectional survey to examine the knowledge level of nurse practitioners (NPs) 
within the primary care setting, concerning IBS pathophysiology, diagnosis, 
and treatment. Overall, the survey found significant deficits in these areas 
that did not correlate with experience level. While the study was small, it 
provides valuable insight into the important role NPs have in understanding 
the disorder and utilizing evidence-based care for the best outcomes.
NPs in the primary care setting can play a vital role in the collaborative 
process of improving the lives of patients with IBS in the following ways:
 Utilize the Rome IV diagnostic criteria to make a positive diagnosis and 
avoid unnecessary tests or procedures.
 Acknowledge that anxiety and depression are common co-morbidities. 
 Understand the current pathophysiology and new advances in the 
treatment of the disorder (Weaver et al., 2017). 
The following educational points can be beneficial in establishing a positive 
relationship with IBS patients in the primary care setting: 
 IBS is a real disorder and not “in your head”. 
 IBS is a chronic condition with symptoms that can vary over time. 
 Quality of life can be significantly impacted with this disorder. 
 Stress can trigger or worsen symptoms.
 There are many options to help manage symptoms, but no “magic pills” 
to cure all the symptoms (Lacy, 2019). 
 Visceral hypersensitivity in IBS is the 
perception of pain in the bowel in response 
to normal GI movement. Abnormalities in 
central pain processing, impaired mucosal 
barrier, inflammation and alterations in gut 
microbiome are possible contributors 
(Chong et al., 2019).
 Visceral hypersensitivity contributes to IBS 
symptoms independent of anxiety and 
depression comorbidity (Simren et al., 2016).
 Concordance for IBS is greater among monozygotic twins. 
Having a parent with IBS tends to be a greater predictor of 
disease, but social learning may be a factor (Hellström, 2019). 
 Polymorphisms in genes responsible for serotonin signaling, 
immune regulation and epithelial barrier function affecting 
intestinal motility have been linked to IBS (Chong et al., 2019). 
 A mutation of a sodium channel gene SCN5A, associated with 
abdominal pain, is the first mutation to be linked to IBS. In a 
large genome-wide association study this mutation was present 
in 2% of patients (Holtmann et al., 2016). 
IBS is a prevalent, chronic GI condition 
associated with recurrent abdominal pain 
and altered bowel habits. Although not 
life- threatening, quality of life can be 
significantly affected. 
The pathophysiology involves a 
complex interaction between the brain 
and gut. Current knowledge has shifted 
focus from a psychologically driven 
etiology to an imbalance of the gut 
microbiome. Future research will likely 
involve the sequencing of the microbiome 
in IBS patients, leading to individualized 
treatment (Chong, et al., 2019). 
